Arcutis Biotherapeutics, Inc. (ARQT) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin rebound ⢠Leverage risk ⢠Rich valuation ARQT's latest quarter showed a sharp profitability and cash-flow rebound, but the full-year record still points to inconsistent earnings, elevated leverage, and a rich valuation despite strong margins and liquidity.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Lower Highs ⢠Failed Breakout Support Level: $22.00â$22.40 Resistance Level: $25.09 ARQT is showing a cautious short-term setup after a volatile last month: it held key support in the $22.00â$22.40 zone and bounced from $21.33, but lower highs since the $25.09 peak signal fading momentum and near-term resistance overhead.
Sentiment & News
Key News Insights: ⢠Pediatric validation ⢠Guideline support ⢠Share selling Arcutis is seeing stronger clinical and guideline support for ZORYVE, even as recent insider and institutional selling adds a cautious tone.
AI Summary
ARQT is transitioning from a speculative dermatology story to a ZORYVE execution story with real revenue scale and improving cash generation, but at ~8.9x sales the market is already pricing in sustained growth, so the key investment question is whether Arcutis can keep compounding revenue fast enough to offset rising commercialization and pipeline spend without any slip in adoption.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |